Literature DB >> 29907227

Lactate dehydrogenase is associated with 28-day mortality in patients with sepsis: a retrospective observational study.

Jun Lu1, Zhonghong Wei2, Hua Jiang1, Lu Cheng1, Qiuhua Chen1, Mingqi Chen1, Jing Yan3, Zhiguang Sun4.   

Abstract

BACKGROUND: Sepsis is a major health care problem, which affects millions of people around the world. Glucose metabolic reprogramming of immune cells plays a crucial role during advancement of sepsis. However, the association between glucose metabolic reprogramming and mortality in patients with sepsis is unclear. Lactate dehydrogenase (LDH) catalyzes the last step of glycolysis. Investigating the relationship between LDH and mortality is important to understand the effect of metabolic reprogramming on prognosis of patients with sepsis.
METHODS: A total of 192 patients with sepsis were included in our study. Data on characteristics of patients, biochemical variables, and inflammatory mediator were collected. Association between the level of serum LDH and 28-day mortality was also analyzed. The correlations between serum LDH, interleukin-1β, creatinine, PaO2/FiO2, and lactate were also observed. The association between LDH and the risk of death was further analyzed. Moreover, receiver operating characteristic curve was depicted to compare the accuracy in prediction of LDH and other variables.
RESULTS: There were statistic difference in 28-day mortality between elevated LDH group and normal LDH group (P = 0.021). Level of serum LDH was an independent risk factor for death of patients with sepsis (hazard ratio 1.005, 95% confidence interval 1.002-1.007, P = 0.001). There were significant correlations between LDH, interleukin-1β (r = 0.514, P = 0.000), creatinine (r = 0.368, P = 0.000), PaO2/FiO2 (r = -0.304, P = 0.000), and lactate (r = 0.560, P = 0.000). The receiver operating characteristic curves showed that the area under the LDH curve for prediction for mortality was 0.783.
CONCLUSIONS: Serum LDH is probably associated with 28-day mortality in patients with sepsis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aerobic glycolysis; Lactic dehydrogenase; Sepsis; Septic shock; Warburg effect

Mesh:

Substances:

Year:  2018        PMID: 29907227     DOI: 10.1016/j.jss.2018.03.035

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Utilization of Deep Learning for Subphenotype Identification in Sepsis-Associated Acute Kidney Injury.

Authors:  Kumardeep Chaudhary; Akhil Vaid; Áine Duffy; Ishan Paranjpe; Suraj Jaladanki; Manish Paranjpe; Kipp Johnson; Avantee Gokhale; Pattharawin Pattharanitima; Kinsuk Chauhan; Ross O'Hagan; Tielman Van Vleck; Steven G Coca; Richard Cooper; Benjamin Glicksberg; Erwin P Bottinger; Lili Chan; Girish N Nadkarni
Journal:  Clin J Am Soc Nephrol       Date:  2020-10-08       Impact factor: 8.237

2.  Epidemiological Characteristics and Mortality Risk Factors Comparison in Dialysis and Non-Dialysis CKD Patients with COVID-19-A Single Center Experience.

Authors:  Andrei Niculae; Ileana Peride; Ana-Maria Nechita; Lucian Cristian Petcu; Mirela Tiglis; Ionel Alexandru Checherita
Journal:  J Pers Med       Date:  2022-06-13

3.  Laboratory biomarker predictors for disease progression and outcome among Egyptian COVID-19 patients.

Authors:  Lamiaa A Fathalla; Lamyaa M Kamal; Omina Salaheldin; Mahmoud A Khalil; Mahmoud M Kamel; Hagar H Fahim; Youssef As Abdel-Moneim; Jawaher A Abdulhakim; Ahmed S Abdel-Moneim; Yomna M El-Meligui
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

4.  Lactic dehydrogenase-lymphocyte ratio for predicting prognosis of severe COVID-19.

Authors:  Guojun Li; Fumin Xu; Xinru Yin; Na Wu; Yuanjie Li; Tinghong Zhang; Dongfeng Chen; Kaijun Liu; Qiu Qiu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

5.  Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19.

Authors:  Murat Seyit; Esin Avci; Rukiye Nar; Hande Senol; Atakan Yilmaz; Mert Ozen; Alten Oskay; Hulya Aybek
Journal:  Am J Emerg Med       Date:  2020-12-06       Impact factor: 2.469

6.  Reply to: Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico.

Authors:  Paulina Vidal-Cevallos; Fatima Higuera-De-La-Tijera; Norberto C Chávez-Tapia; Francisco Sánchez-Girón; Eira Cerda Reyes; Victor Hugo Rosales-Salyano; Alfredo Servin-Caamaño; Martín Uriel Vázquez-Medina; Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2021-04-24       Impact factor: 3.388

7.  Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study.

Authors:  Paulina Vidal-Cevallos; Fatima Higuera-De-La-Tijera; Norberto C Chávez-Tapia; Francisco Sanchez-Giron; Eira Cerda-Reyes; Victor Hugo Rosales-Salyano; Alfredo Servin-Caamaño; Martín Uriel Vázquez-Medina; Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2021-02-26       Impact factor: 3.388

8.  Association of Lactate Dehydrogenase with In-Hospital Mortality in Patients with Acute Aortic Dissection: A Retrospective Observational Study.

Authors:  Huaping He; Xiangping Chai; Yang Zhou; Xiaogao Pan; Guifang Yang
Journal:  Int J Hypertens       Date:  2020-01-07       Impact factor: 2.420

9.  Serum hydroxybutyrate dehydrogenase as an early predictive marker of the severity of acute pancreatitis: a retrospective study.

Authors:  Weiming Xiao; Weili Liu; Ling Yin; Yong Li; Guotao Lu; Xinnong Liu; Weijuan Gong; Yanbing Ding; Mei Wang; Zhigang Yan
Journal:  BMC Gastroenterol       Date:  2020-11-20       Impact factor: 3.067

10.  Growth Arrest-Specific Gene 6 Administration Ameliorates Sepsis-Induced Organ Damage in Mice and Reduces ROS Formation In Vitro.

Authors:  Livia Salmi; Francesco Gavelli; Filippo Patrucco; Mattia Bellan; Pier Paolo Sainaghi; Gian Carlo Avanzi; Luigi Mario Castello
Journal:  Cells       Date:  2021-03-09       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.